Approval · Notice of Compliance 38279 · 2026
GABAPENTIN: Notice of Compliance 38279
Issued September 14, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 38279
- Date
- September 14, 2026
- Company
- Sivem Pharmaceuticals UlcSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement between two manufacturers
- Canadian reference product
- NEURONTIN (Upjohn Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| GABAPENTIN | 02246314 | Marketed |
| GABAPENTIN | 02246315 | Marketed |
| GABAPENTIN | 02246316 | Marketed |
Medicinal ingredients
- GABAPENTIN 100 MG per CAP
- GABAPENTIN 300 MG per CAP
- GABAPENTIN 400 MG per CAP